These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. A scoping review of hormonal clinical trials in menstrual cycle-related brain disorders: Studies in premenstrual mood disorder, menstrual migraine, and catamenial epilepsy. Barone JC; Butler MP; Ross A; Patterson A; Wagner-Schuman M; Eisenlohr-Moul TA Front Neuroendocrinol; 2023 Oct; 71():101098. PubMed ID: 37619655 [TBL] [Abstract][Full Text] [Related]
7. The use of gonadotrophin-releasing hormone (GnRH) agonists in early and advanced breast cancer in pre- and perimenopausal women. Robertson JF; Blamey RW Eur J Cancer; 2003 May; 39(7):861-9. PubMed ID: 12706354 [TBL] [Abstract][Full Text] [Related]
8. Pre-operative endometrial thinning agents before endometrial destruction for heavy menstrual bleeding. Sowter MC; Lethaby A; Singla AA Cochrane Database Syst Rev; 2002; (3):CD001124. PubMed ID: 12137619 [TBL] [Abstract][Full Text] [Related]
9. Vesicular Contact Reaction May Progress into Erythema Multiforme. Czarnecka-Operacz M; Jenerowicz D; Szulczyńska-Gabor J; Teresiak-Mikołajczak E; Szyfter-Harris J; Bowszyc-Dmochowska M Acta Dermatovenerol Croat; 2016 Dec; 24(4):307-309. PubMed ID: 28128086 [TBL] [Abstract][Full Text] [Related]
10. Comparable effectiveness using flexible single-dose GnRH antagonist (cetrorelix) and single-dose long GnRH agonist (goserelin) protocol for IVF cycles--a prospective, randomized study. Vlaisavljevic V; Reljic M; Lovrec VG; Kovacic B Reprod Biomed Online; 2003 Oct; 7(3):301-8. PubMed ID: 14653888 [TBL] [Abstract][Full Text] [Related]
12. Protective effect of goserelin on ovarian reserve during (neo)adjuvant chemotherapy in young breast cancer patients: a prospective cohort study in China. Wang S; Pei L; Hu T; Jia M; Wang S Hum Reprod; 2021 Mar; 36(4):976-986. PubMed ID: 33411897 [TBL] [Abstract][Full Text] [Related]
13. Gene expression and tissue concentrations of IGF-I in human myometrium and fibroids under different hormonal conditions. Englund K; Lindblom B; Carlström K; Gustavsson I; Sjöblom P; Blanck A Mol Hum Reprod; 2000 Oct; 6(10):915-20. PubMed ID: 11006320 [TBL] [Abstract][Full Text] [Related]
14. Autoimmune Progesterone Dermatitis Diagnosed by Lymphocyte Transformation Test and Progesterone Provocation Test. Ljubojević Hadžavdić S; Marinović Kulišić S; Ljubojević Grgec D; Poljanac A; Ilić B Acta Dermatovenerol Croat; 2018 Oct; 26(3):276-277. PubMed ID: 30390735 [TBL] [Abstract][Full Text] [Related]
15. Aromatization inhibition alone or in combination with GnRH agonists for the treatment of premenopausal breast cancer patients. Dowsett M; Stein RC; Coombes RC J Steroid Biochem Mol Biol; 1992 Sep; 43(1-3):155-9. PubMed ID: 1388047 [TBL] [Abstract][Full Text] [Related]
16. Endocrinologic and clinical evaluation following a single administration of a gonadotrophin-releasing hormone agonist (Zoladex), in a depot formulation, to premenopausal women. Matta WH; Shaw RW; Burford GD Fertil Steril; 1988 Jan; 49(1):163-5. PubMed ID: 2961621 [TBL] [Abstract][Full Text] [Related]
17. Pre-operative endometrial thinning agents before hysteroscopic surgery for heavy menstrual bleeding. Sowter MC; Singla AA; Lethaby A Cochrane Database Syst Rev; 2000; (2):CD001124. PubMed ID: 10796747 [TBL] [Abstract][Full Text] [Related]
18. Recurrent anaphylaxis associated with gonadotropin-releasing hormone analogs: case report and review of the literature. Lam C; Tjon J; Hamilton J; Ahmet AH Pharmacotherapy; 2006 Dec; 26(12):1811-5. PubMed ID: 17125443 [TBL] [Abstract][Full Text] [Related]
19. Prevention of chemotherapy-induced menopause by temporary ovarian suppression with goserelin in young, early breast cancer patients. Del Mastro L; Catzeddu T; Boni L; Bell C; Sertoli MR; Bighin C; Clavarezza M; Testa D; Venturini M Ann Oncol; 2006 Jan; 17(1):74-8. PubMed ID: 16254024 [TBL] [Abstract][Full Text] [Related]